{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:03:56Z","timestamp":1794225836002,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112924","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:32:33Z","timestamp":1759012353000},"page":"112924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review"],"prefix":"10.1016","volume":"229","author":[{"given":"Dimitrios","family":"Pantazopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112924_b0005","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.diabres.2025.112924_b0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112924_b0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2025.112924_b0020","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112924_b0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabres.2025.112924_b0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.112924_b0035","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jgs.16372","article-title":"Sarcopenia definition: the position statements of the sarcopenia definition and outcomes consortium","volume":"68","author":"Bhasin","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.diabres.2025.112924_b0040","first-page":"339","article-title":"Sarcopenic obesity and weight loss-induced muscle mass loss","volume":"28","author":"Caturano","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.diabres.2025.112924_b0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabres.2025.112924_b0050","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1055\/s-2004-826178","article-title":"GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"36","author":"Ahren","year":"2004","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabres.2025.112924_b0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.112924_b0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-023-01506-1","article-title":"Potential new therapeutic implications of semaglutide: new colours of the rainbow?","volume":"15","author":"Gouveri","year":"2024","journal-title":"Diabetes Ther"},{"issue":"12","key":"10.1016\/j.diabres.2025.112924_b0075","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112924_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126769","article-title":"The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis","volume":"10","author":"Potts","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.diabres.2025.112924_b0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2025.112924_b0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/DMSO.S193693","article-title":"Comparative effectiveness of long-acting GLP-1 receptor agonists in type 2 diabetes: a short review on the emerging data","volume":"13","author":"Chudleigh","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.diabres.2025.112924_b0095","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/d41573-019-00177-7","article-title":"FDA new drug approvals in Q3 2019","volume":"18","author":"Urquhart","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.diabres.2025.112924_b0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10278","key":"10.1016\/j.diabres.2025.112924_b0105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u20224 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.diabres.2025.112924_b0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112924_b0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.diabres.2025.112924_b0120","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1210\/en.2018-00399","article-title":"Team players or opponents: coadministration of selective glucagon and GLP-1 receptor agonists in obese diabetic monkeys","volume":"159","author":"Elvert","year":"2018","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.diabres.2025.112924_b0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0130","unstructured":"European Medicines Agency. Ozempic: EPAR \u2013 Product Information. EMA. Published October 17, 2018. Updated June 27, 2024. Accessed July 7, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic."},{"key":"10.1016\/j.diabres.2025.112924_b0135","unstructured":"European Medicines Agency. Mounjaro: EPAR \u2013 Product Information. EMA. Published September 15, 2023. Accessed July 7, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro."},{"issue":"10191","key":"10.1016\/j.diabres.2025.112924_b0140","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","article-title":"Sarcopenia","volume":"393","author":"Cruz-Jentoft","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2025.112924_b0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.diabres.2025.112924_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1556\/650.2021.32015","article-title":"Sarcopenia\u20142021: pathophysiology, diagnosis, therapy","volume":"162","author":"P\u00e1r","year":"2021","journal-title":"Orv Hetil"},{"issue":"7","key":"10.1016\/j.diabres.2025.112924_b0155","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.ijo.0800910","article-title":"Determinants of energy expenditure and fuel utilization in man: effects of body composition, age, sex, ethnicity and glucose tolerance in 916 subjects","volume":"23","author":"Weyer","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.diabres.2025.112924_b0160","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes Facts"},{"key":"10.1016\/j.diabres.2025.112924_b0165","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jgs.12260","article-title":"Variation in the prevalence of sarcopenia and sarcopenic obesity in older adults associated with different research definitions: dual-energy X-ray absorptiometry data from the National Health and Nutrition Examination Survey 1999-2004","volume":"61","author":"Batsis","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabres.2025.112924_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2020.569904","article-title":"Exploring the impact of obesity on skeletal muscle function in older age","volume":"7","author":"Morgan","year":"2020","journal-title":"Front Nutr"},{"key":"10.1016\/j.diabres.2025.112924_b0175","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13098-021-00707-7","article-title":"The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta\u2010analysis","volume":"13","author":"Ai","year":"2021","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.diabres.2025.112924_b0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/15347346221111420","article-title":"Sarcopenia, frailty and diabetic foot: a mini narrative review","volume":"23","author":"Karakousis","year":"2024","journal-title":"Int J Low Extrem Wounds"},{"issue":"5","key":"10.1016\/j.diabres.2025.112924_b0185","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s11255-022-03392-1","article-title":"Frailty, sarcopenia and diabetic kidney disease: where do we stand?","volume":"55","author":"Karakousis","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.diabres.2025.112924_b0190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/jgs.12652","article-title":"Sarcopenic obesity and risk of cardiovascular disease and mortality: a population\u2010based cohort study of older men","volume":"62","author":"Atkins","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.diabres.2025.112924_b0195","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdi.12658","article-title":"Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes","volume":"9","author":"Nomura","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"10","key":"10.1016\/j.diabres.2025.112924_b0200","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00198-017-4151-8","article-title":"Osteosarcopenia: where bone, muscle, and fat collide","volume":"28","author":"Hirschfeld","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.diabres.2025.112924_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.diabres.2025.112924_b0210","unstructured":"ClinicalTrials.gov. Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetes (SUSTAIN 8). Novo Nordisk A\/S. Published May 4, 2017. Updated January 30, 2024. Accessed July 9, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03136484."},{"key":"10.1016\/j.diabres.2025.112924_b0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2025.112924_b0220","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0225","unstructured":"ClinicalTrials.gov. A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1). Published November 29, 2019. Updated June 24, 2024. Accessed July 9, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04184622."},{"issue":"5","key":"10.1016\/j.diabres.2025.112924_b0230","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/jcsm.13524","article-title":"Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation","volume":"15","author":"Huang","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.diabres.2025.112924_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105656","article-title":"Worldwide burden of antidiabetic drug-induced sarcopenia: an international pharmacovigilance study","volume":"129","author":"Kong","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.diabres.2025.112924_b0240","doi-asserted-by":"crossref","DOI":"10.1007\/s12178-025-09978-3","article-title":"The effects of GLP-1 agonists on musculoskeletal health and orthopedic care","author":"Gatto","year":"2025","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"Suppl 4","key":"10.1016\/j.diabres.2025.112924_b0245","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2025.112924_b0250","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.112924_b0255","unstructured":"ClinicalTrials.gov. A study of tirzepatide (LY3298176) versus insulin degludec in participants with type 2 diabetes (SURPASS-3). Published March 21, 2019. Updated June 24, 2024. Accessed July 7, 2025. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03882970."},{"key":"10.1016\/j.diabres.2025.112924_b0260","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9926462","article-title":"dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts","volume":"2023","author":"Deng","year":"2023","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.diabres.2025.112924_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"issue":"18","key":"10.1016\/j.diabres.2025.112924_b0270","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.diabres.2025.112924_b0275","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"10.1016\/j.diabres.2025.112924_b0280","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112924_b0285","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.23098","article-title":"Liraglutide does not adversely impact fat-free mass loss","volume":"29","author":"Grannell","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.diabres.2025.112924_b0290","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.diabres.2025.112924_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2025.112924_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.diabres.2025.112924_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101681","article-title":"GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0310","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"12","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.diabres.2025.112924_b0315","article-title":"The anabolic response to protein ingestion during recovery from exercise has no upper limit in magnitude and duration in vivo in humans","volume":"4","author":"Trommelen","year":"2023","journal-title":"Cell Rep Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112924_b0320","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.celrep.2016.09.047","article-title":"High-protein intake during weight loss therapy eliminates the weight-loss-induced improvement in insulin action in obese postmenopausal women","volume":"17","author":"Smith","year":"2016","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.diabres.2025.112924_b0325","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112924_b0330","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3945\/an.116.014506","article-title":"Preserving healthy muscle during weight loss","volume":"8","author":"Cava","year":"2017","journal-title":"Adv Nutr"},{"key":"10.1016\/j.diabres.2025.112924_b0335","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/jc.2008-1357","article-title":"Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis","volume":"94","author":"Mekala","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112924_b0340","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","author":"Ryan","year":"2025","journal-title":"Rev in Endocr Metab Disord"},{"issue":"10","key":"10.1016\/j.diabres.2025.112924_b0345","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.diabres.2025.112924_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112924_b0355","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin a blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.diabres.2025.112924_b0360","article-title":"Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial JAMA","volume":"4","author":"Heymsfield","year":"2021","journal-title":"Netw Open"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:22:53Z","timestamp":1764080573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":72,"alternative-id":["S0168822725009386"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112924","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112924"}}